

What is claimed is:

1. A transfer factor effective to confer cell-mediated immunity wherein the immune response is to Human Herpesvirus-6A and Human Herpesvirus-6B.
2. A transfer factor effective to confer cell-mediated immunity wherein the immune response is to Human Herpesvirus-6A or Human Herpesvirus-6B
3. A method of producing the transfer factor of claim 1 or 2 which comprises immunizing a lactating animal with Human Herpesvirus-6A and Human Herpesvirus-6B, recovering colostrum from the animal, and preparing the transfer factor from the colostrum.
4. The method of claim 3 wherein the animal is a bovid.
5. A method of producing the transfer factor of claim 1 or 2 which comprises immunizing an animal with Human Herpesvirus-6A and Human Herpesvirus-6B, recovering an immune system component from the animal, and preparing the transfer factor from the immune system component.
6. The method of claim 5 wherein the immune system component is dialyzable leukocyte extract.

7. The method of claim 5 wherein the immune system component is immune organ lysate.
8. The method of claim 5 wherein the immune system component is a cell line derived from an immune system component.
9. The method of claim 5 wherein the immune system component is a lymphoblastoid cell.
10. A method of producing a composition which comprises producing the transfer factor of claim 3 or 5 and admixing a carrier.
11. A method of producing a composition which comprises producing the transfer factor of claim 3 or 5 and admixing a carrier wherein the carrier is a pharmaceutically acceptable carrier.
12. A method of producing a composition which comprises producing the transfer factor of claim 3 or 5 and admixing a carrier wherein the carrier is an edible carrier.
13. A method of treating Chronic Fatigue Syndrome in a subject, which comprises administering to the subject an amount of Human Herpesvirus-6A and Human Herpesvirus-6B transfer factors effective to treat the Chronic Fatigue Syndrome.

14. A method of treating Multiple Sclerosis in a subject, which comprises administering to the subject an amount of Human Herpesvirus-6 transfer factor effective to treat the Multiple Sclerosis.
- 5
15. A method of treating Multiple Sclerosis in a subject, which comprises administering to the subject an amount of Human Herpesvirus-6A and Human Herpesvirus-6B transfer factors effective to
- 10 treat the Multiple Sclerosis.
16. A method of treating an abnormality in a subject, which comprises administering to the subject an amount of the transfer factor of claim 2 effective
- 15 to alleviate the abnormality, wherein the abnormality is alleviated by enhancing the subject's immune response to Human Herpesvirus-6A.
17. A method of treating an abnormality in a subject, which comprises administering to the subject an
- 20 amount of the transfer factor of claim 2 effective to alleviate the abnormality, wherein the abnormality is alleviated by enhancing the subject's immune response to Human Herpesvirus-6B.
- 25
18. A method of treating an abnormality in a subject, which comprises administering to the subject an amount of the transfer factor of claim 1 effective
- 30 to alleviate the abnormality, wherein the abnormality is alleviated by enhancing the

subject's immune response to Human Herpesvirus-6A
and Human Herpesvirus-6B.

5 19. A composition comprising the transfer factor of
claim 1 or 2 and a carrier.

20. A composition comprising the transfer factor of
claim 1 or 2 and a carrier, wherein the carrier is
a pharmaceutically acceptable carrier.

10

21. A composition comprising the transfer factor of
claim 1 or 2 and a carrier, wherein the transfer
factor is present in an amount effective to
enhance a subject's immune response.

15

22. A composition comprising the transfer factor of
claim 1 or 2 and a carrier, wherein the carrier is
a pharmaceutically acceptable carrier and wherein
the transfer factor is present in an amount
effective to enhance a subject's immune response.

20

23. A composition comprising the transfer factor of
claim 1 or 2 and a carrier, wherein the carrier is
an edible carrier and wherein the transfer factor
is present in an amount effective to enhance a
subject's immune response.

25

24. The composition of claim 19, wherein the transfer
factor is capable of passing through a cell
membrane.

30

25. Use of the transfer factor of claim 2 for the preparation of a pharmaceutical composition for treating an abnormality, wherein the abnormality is alleviated by enhancing the subject's immune response to Human Herpesvirus-6A.
26. Use of the transfer factor of claim 2 for the preparation of a pharmaceutical composition for treating an abnormality, wherein the abnormality is alleviated by enhancing the subject's immune response to Human Herpesvirus-6B.
27. Use of the transfer factor of claim 1 for the preparation of a pharmaceutical composition for treating an abnormality, wherein the abnormality is alleviated by enhancing the subject's immune response to Human Herpesvirus-6A and Human Herpesvirus-6B.
28. An edible composition comprising the transfer factor of claim 1 or 2 in an amount effective to enhance a person's immune response and an edible carrier.
29. A method of enhancing a person's immune response by administering to the person an amount of the composition of claim 28 effective to enhance a person's immune response.